Prospective clinical trials needed to validate the findings ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major cardiovascular event among adults with atherosclerotic cardiovascular disease ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...

Enlicitide decanoate statistically significantly reduced LDL-C compared with placebo (CORALreef HeFH) and vs other oral non-statin therapies (CORALreef AddOn). Topline data were announced from two ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A recent study, published in JAMA on November 9, investigates a drug called enlicitide. The ...